Sino Biological financials at a glance
| Year | Year | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
¥965.27M | ¥574.60M | ¥646.39M | ¥0.00M |
| GM % | Gross Margin % |
|
92.85% | 83.47% | 80.53% | 0.00% |
| OM | Operating Margin |
|
72.16% | 35.42% | 21.00% | 0.00% |
| EPS | Earnings Per Share |
|
¥5.54 | ¥2.15 | ¥1.30 | ¥0.00 |
| Div. | Dividends |
|
¥5.26 | ¥2.00 | ¥2.00 | ¥0.00 |
| PR % | Payout Ratio % |
|
94.95% | 93.02% | 153.85% | 0 |
| Sha. | Shares |
|
68m | 129.2m | 0m | 127.76m |
| OCF | Operating Cash Flow |
|
¥642.62M | ¥249.39M | ¥322.56M | ¥0.00M |
| FCF | Free Cash Flow |
|
¥594.72M | ¥93.33M | ¥-720.80M | ¥0.00M |
| FCFS | Free Cash Flow Per Share |
|
¥5.52 | ¥0.82 | ¥-5.58 | ¥0.00 |